Belite Bio, Inc
BLTE
Positions held
Your positionsBLTE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Belite Bio, Inc. operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and solutions, attracting significant investor interest.
- The company has a market capitalization of approximately $6.27 billion, indicating strong investor confidence.
- Belite Bio's target mean price is $228.89, suggesting a substantial upside potential from its current trading levels.
- Belite Bio, Inc. has reported no revenue over the past several quarters, which raises concerns about its financial viability.
- The company's net income for 2025 is projected to be -$77.611 million, reflecting ongoing financial losses.
- Belite Bio has a profit margin of 0.0%, indicating it has not yet achieved profitability.
Fundamentals
| Market cap | $6.14B | Enterprise value | — | Trailing P/E | — | Forward P/E | 67.49 |
| PEG | — | Price / book | 7.91 | Beta | -1.23 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -22.1% | ROA | -15.7% | Debt / equity | — |
| Current ratio | 33.56 | Free cash flow | — | Analyst recommendation | none | Mean target | $228.89 |
| 52w high | $200.00 | 52w low | $77.13 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$28.4M | -$26.9M | -$25.3M | -$21.7M | -$16.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$34.9M | -$32.7M | -$28.1M | -$23.0M | -$17.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$77.6M | -$36.1M | -$31.6M | -$12.6M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$84.2M | -$40.0M | -$31.7M | -$12.8M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
2026-09-29 · Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
2026-09-10 · Belite Bio Insider Sold Shares Worth $12,803,528, According to a Recent SEC Filing
2026-09-09 · Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
2026-09-09 · Mizuho Raises Price Target on Belite Bio to $234 From $220, Keeps Outperform Rating
2026-09-08 · Belite Bio Submits Japan Application for Stargardt Disease Drug
2026-09-04 · Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating
2026-09-04 · Belite Bio's Tinlarebant Revenue Estimates Have Multiple Drivers of Upside, Mizuho Says
2026-09-04 · UiPath downgraded, Shell upgraded: Wall Street's top analyst calls
2026-09-04 · Canaccord Genuity Initiates Belite Bio at Buy With $303 Price Target
Price (daily)
Full chart · RSI · MACD · patterns